Merck’s Gefapixant (Lyfnua) for chronic cough do not find favour with FDA Adcom Read More..

Merck in a statement announced that FDA’s advisory committee voted 12-1 that Gefapixant do not provide a clinically meaningful benefit to adults with refractory or unexplained chronic cough. Chronic cough is defined as a cough lasting longer than eight weeks and underlying chronic cough (UCC) is where the underlying cause cannot be identified despite a thorough evaluation.

Gefapixant(Lyfnua) is approved in Europe for chronic cough in Sep 2023.